Injectafer denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for injectafer are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare May Issue a "Not FDA-Approved" Denial for Injectafer

Injectafer (ferric carboxymaltose) holds FDA approval for intravenous treatment of iron deficiency anemia in specific adult patient populations — the approval and its scope are described in the FDA-approved prescribing information, which is publicly available. A "not FDA-approved" denial from UnitedHealthcare for Injectafer almost always means one of two things: (1) the plan is asserting that the proposed use falls outside Injectafer's approved indication, or (2) there has been a coding or administrative error in how the claim was submitted. Both are appealable.

## Why This Denial Is Appealable

If your use falls within Injectafer's FDA-approved indication, the denial is factually incorrect and must be corrected on appeal. If the use is off-label, the analysis shifts to whether the off-label use is supported by peer-reviewed evidence and recognized clinical compendia — and many off-label uses are nonetheless covered under applicable standards. An insurer cannot categorically deny a drug solely because a particular use is off-label if that use is recognized by an authoritative clinical body.

## Your Federal Appeal Rights

• Internal appeal: File immediately, citing the FDA approval status and the specific approved indication. Attach the relevant section of the FDA-approved label.
• External review (ACA §2719): Request independent external review after the internal process. The external reviewer will assess whether the denial accurately characterizes the drug's approval status and whether the clinical standard supports coverage.
• ERISA §503: For employer self-funded plans, demand the full administrative record, including the clinical rationale used by the plan's reviewing clinician.
• Expedited review: Available if the clinical situation is urgent.
• Timeline: External review must generally be requested within four months of the final internal denial.

## Documentation to Gather

1. FDA prescribing information: Download the current FDA-approved label for Injectafer directly from the FDA website or the manufacturer. Identify the approved indication and confirm your use falls within it. 2. Diagnosis confirmation: Clinical notes, lab results, and specialist records establishing that your diagnosis matches the approved indication. 3. Prescriber letter: Your clinician should state explicitly that the prescribed use is within the FDA-approved indication (or, if off-label, cite the authoritative clinical compendia or guideline organization supporting that use). 4. Claim submission records: Obtain the EOB and confirm the diagnosis and procedure codes submitted; a coding mismatch can generate a spurious "not approved" denial. 5. UHC's clinical policy: Review UHC's published policy on Injectafer to understand the exact coverage criteria being applied.

## Criteria-Mapping Structure

Your appeal letter should open by quoting the FDA-approved indication directly from the label, then state plainly that your diagnosis and clinical circumstances match that indication. Use the two-column mapping table — left: each coverage criterion from UHC's published policy; right: the chart fact or document that satisfies it. If the denial was administrative in nature (a coding error), document that separately and request a corrected claim reprocessing in addition to the appeal.